

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

# **WHO Expert Committee on Biological Standardization**

---

Fortieth Report

World Health Organization  
Technical Report Series  
800



World Health Organization, Geneva 1990

WHO Library Cataloguing in Publication Data

WHO Expert Committee on Biological Standardization

WHO Expert Committee on Biological Standardization : fortieth report.

(World Health Organization technical report series ; 800)

1. Biological products – standards I. Series

ISBN 92 4 120800 7

(NLM Classification: QW 800)

ISSN 0512-3054

© World Health Organization 1990

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

90/8566 – Schöfer SA – 7000

# CONTENTS

	Page
<b>General</b>	
Guidelines for assuring the quality of pharmaceutical and biological products made by recombinant DNA technology .....	9
Distribution of international reference materials by the four International Laboratories for Biological Standards .....	10
WHO bank of Vero cells for the production of biologicals .....	11
Reference materials for clinical diagnostic methods .....	11
Guidelines on the national control of vaccines and sera .....	12
One-dilution potency tests for vaccines containing diphtheria and tetanus toxoid .....	12
Potency determination of the diphtheria component of DT and DTP vaccines in mice .....	13
WHO collaborative study on the reliability of laboratory estimates of the potency of oral poliomyelitis vaccine .....	13
Thermal stability of current oral poliomyelitis vaccines .....	14
<b>SUBSTANCES</b>	
<b>Antibiotics</b>	
1. Netilmicin .....	15
2. Clindamycin .....	15
3. Lincomycin .....	15
4. Cefalotin .....	15
5. Procaine benzylpenicillin in oil with aluminium monostearate .....	16
<b>Antibodies</b>	
6. Anti-toxoplasma IgM serum .....	16
7. Antisera for typing agglutinogens of pertussis strains .....	16
<b>Antigens</b>	
8. Stability of the International Reference Reagent for the Assay of Measles Vaccine (Live) .....	17
9. Stability of the second International Standard for Pertussis Vaccine .....	17
<b>Blood products and related substances</b>	
10. High molecular weight urokinase .....	18
11. Streptokinase .....	18
12. Human blood coagulation factor VIII:C concentrate .....	19
13. Low molecular weight heparin .....	19
14. Apolipoproteins A-I and B .....	20
15. Haemiglobincyanide .....	20
	3

## Endocrinological and related substances

16. Erythropoietin .....	21
17. Thyroid-stimulating antibodies .....	21
18. Salmon calcitonin .....	21
19. Eel calcitonin .....	22
20. Renin .....	22

## Cytokines

21. Interleukin-1 alpha .....	22
22. Interleukin-1 beta .....	23
23. Interleukin-3 .....	23
24. Interleukin-4 .....	23
25. Interleukin-6 .....	24
26. Interleukin-8 .....	24
27. Granulocyte/macrophage colony-stimulating factor .....	24
28. Granulocyte colony-stimulating factor .....	24
29. Macrophage colony-stimulating factor .....	25
30. Tumour necrosis factor, alpha .....	25
31. Tumour necrosis factor, beta .....	25
32. Transforming growth factor, beta 1 .....	25
33. Transforming growth factor, beta 2 .....	26

## REQUIREMENTS FOR BIOLOGICAL SUBSTANCES

34. Requirements for poliomyelitis vaccine (oral) .....	26
35. Requirements for diphtheria, tetanus, pertussis and combined vaccines ....	26
36. Requirements for antimicrobial susceptibility tests	
1. Agar diffusion tests using antimicrobial susceptibility discs (addendum 1989) .....	27
37. Guidelines for the preparation, characterization and establishment of international and other standards and reference reagents for biological substances .....	28
38. General requirements for manufacturing establishments and control laboratories .....	28
39. Discontinuance of the Requirements for Procaine Benzylpenicillin in Oil with Aluminium Monostearate .....	29

## ANNEXES

Annex 1. Requirements for poliomyelitis vaccine (oral) (revised 1989) .....	30
Annex 2. Requirements for diphtheria, tetanus, pertussis and combined vaccines (revised 1989) .....	87
Annex 3. Requirements for antimicrobial susceptibility tests	
1. Agar diffusion tests using antimicrobial susceptibility discs (addendum 1989) .....	180

Annex 4.	Guidelines for the preparation, characterization and establishment of international and other standards and reference reagents for biological substances (revised 1989) .....	181
Annex 5.	Biological substances: international standards and reference reagents.....	215
Annex 6.	Requirements for biological substances and other documents .....	217

## WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 24–31 October 1989

### Members\*

- Dr D. Calam, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Chairman*)  
Dr J. Furesz, Director, Bureau of Biologics, Drugs Directorate, Tunney's Pasture, Ottawa, Ontario, Canada  
Mr J. Lyng, Head, Laboratory for Biological Standards, State Serum Institute, Copenhagen, Denmark  
Professor A.N.U. Njoku-Obi, Head, Department of Medical Microbiology, University of Nigeria (College of Medicine), Enugu, Nigeria  
Dr S.N. Saxena, Director, Central Research Institute, Kasauli, India  
Dr V. Takla-Rizk, Egyptian Organization for Biological Products and Vaccines, Agouza, Cairo, Egypt (*Vice-Chairman*)  
Dr M.S. Vorobyova, Department of Virology, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, USSR  
Dr W.W. Wright, Drug Standards Division, United States Pharmacopeia, The National Formulary, Rockville, MD, USA (*Rapporteur*)

### Representatives of other organizations

#### *Commission of the European Communities*

Dr E. Colinet, Community Bureau of Reference, Brussels, Belgium

#### *Council of Europe*

Mr J.-M. Spieser, European Pharmacopoeia, Strasbourg, France

#### *International Association of Biological Standardization*

Professor W. Hennessen, Bern, Switzerland

#### *International Federation of Pharmaceutical Manufacturers Associations (IFPMA)*

Dr F. Burkhardt, IFPMA, Geneva, Switzerland

Dr J. Peetermans, IFPMA, Geneva, Switzerland

### Secretariat

- Dr V. Grachev, Scientist, Biologicals, WHO, Geneva, Switzerland  
Dr C. Guthrie, Commonwealth Serum Laboratories, Parkville, Victoria, Australia (*Temporary Adviser*)  
Dr M.C. Hardegree, Director, Office of Biologics Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA (*Temporary Adviser*)

---

\* Unable to attend: Dr K. Fukai, Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan; Dr Zhou Zhao Zheng, Head, Division of Biological Standards and Control, Shanghai Institute for Biological Products, Shanghai, China.

Dr S.L. Jeffcoate, Head, Department of Endocrinology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)  
Mr P. Lemoine, Institute of Hygiene and Epidemiology, Brussels, Belgium (*Temporary Adviser*)  
Dr D. Magrath, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)  
Dr J. Miltien, Scientist, Biologicals, WHO, Geneva, Switzerland  
Dr R. Netter, Director-General, National Health Laboratory, Ministry of Solidarity, Health, and Social Protection, Paris, France (*Temporary Adviser*)  
Dr P. Sizaret, Scientist, Biologicals, WHO, Geneva, Switzerland  
Dr D. Thomas, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)  
Dr W.G. von Aken, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Temporary Adviser*)

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30763](https://www.yunbaogao.cn/report/index/report?reportId=5_30763)

